Filing Details
- Accession Number:
- 0001209191-21-011010
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-02-16 19:43:50
- Reporting Period:
- 2021-02-11
- Accepted Time:
- 2021-02-16 19:43:50
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1714899 | Denali Therapeutics Inc. | DNLI | Biological Products, (No Disgnostic Substances) (2836) | 463872213 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1724605 | Carole Ho | C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2021-02-11 | 2,756 | $70.17 | 172,633 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2021-02-11 | 400 | $71.49 | 172,233 | No | 4 | S | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 25,000 | Indirect | See footnote |
Common Stock | 82,382 | Direct |
Footnotes
- Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $69.79 to $70.74 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- Includes 7,468 shares acquired pursuant to vesting of restricted stock units and issued directly to the Rohatgi-Ho Family 2009 Revocable Trust.
- The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
- The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $71.01 to $71.705 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- The shares are held of record by The Rohatgi-Ho Irrevocable GST Trust, for which the Reporting Person serves as trustee.
- The Reporting Person has reported prior awards of restricted stock units in Table II of Form 4. This total reported in Column 5 includes 80,906 previously reported restricted stock units.